Sökning: id:"swepub:oai:DiVA.org:oru-102187" >
Model-based predict...
-
Nilsson, KristofferThe Swedish Institute for Health Economics, Lund, Sweden
(författare)
Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
-
2022-12-02
-
Wiley-Blackwell Publishing Inc.2023
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:oru-102187
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-102187URI
-
https://doi.org/10.1111/dom.14921DOI
-
https://lup.lub.lu.se/record/1c4b9a3a-5abc-4162-b9c7-8530e8627b2eURI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding agency:Boehringer Ingelheim
-
AIM: To perform a model-based analysis of the short- and long-term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden.MATERIALS AND METHODS: The validated Institute for Health Economics Diabetes Cohort Model (IHE-DCM) was used to estimate health benefits and 3-years' budget impact, and lifetime costs per quality-adjusted life year (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n=131,412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results.RESULTS: Over 3 years, SoC with empagliflozin (100% implementation) vs. SoC before empagliflozin resulted in 7,700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 6% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost-effectiveness ratio of €16,000 EUR per QALY vs. SoC before empagliflozin.CONCLUSIONS: Model simulations using real-world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even in a short-term perspective.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Andersson, EmelieThe Swedish Institute for Health Economics, Lund, Sweden
(författare)
-
Persson, SofieLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)med-sep
(författare)
-
Karlsdotter, KristinaBoehringer Ingelheim AB, Stockholm, Sweden(Swepub:lu)med-kkd
(författare)
-
Skogsberg, JosefinBoehringer Ingelheim AB, Stockholm, Sweden
(författare)
-
Gustavsson, StaffanBoehringer Ingelheim AB, Stockholm, Sweden
(författare)
-
Jendle, Johan,1963-Örebro universitet,Institutionen för medicinska vetenskaper,Boehringer Ingelheim AB(Swepub:oru)jje
(författare)
-
Steen Carlsson, KatarinaLund University,Lunds universitet,Hälsoekonomi,Forskargrupper vid Lunds universitet,Health Economics,Lund University Research Groups,IHE – The Swedish Institute for Health Economics(Swepub:lu)smi-ks0
(författare)
-
The Swedish Institute for Health Economics, Lund, SwedenHälsoekonomi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Diabetes, obesity and metabolism: Wiley-Blackwell Publishing Inc.25:3, s. 748-7571462-89021463-1326
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Kristof ...
-
Andersson, Emeli ...
-
Persson, Sofie
-
Karlsdotter, Kri ...
-
Skogsberg, Josef ...
-
Gustavsson, Staf ...
-
visa fler...
-
Jendle, Johan, 1 ...
-
Steen Carlsson, ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Endokrinologi oc ...
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Hälsovetenskap
-
och Hälso och sjukvå ...
- Artiklar i publikationen
-
Diabetes, obesit ...
- Av lärosätet
-
Örebro universitet
-
Lunds universitet